Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

WormBase: A Model Organism Database.

Dubaj Price M, Hurd DD.

Med Ref Serv Q. 2019 Jan-Mar;38(1):70-80. doi: 10.1080/02763869.2019.1548896.

PMID:
30942676
2.

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6.

3.

Tubulins in C. elegans.

Hurd DD.

WormBook. 2018 Aug 4;2018:1-32. doi: 10.1895/wormbook.1.182.1. Review.

4.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL.

Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: Lancet Haematol. 2018 Aug;5(8):e332. Lancet Haematol. 2018 Dec;5(12):e608.

5.

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.

Voorhees PM, Gasparetto C, Moore DT, Winans D, Orlowski RZ, Hurd DD.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):424-432. doi: 10.1016/j.clml.2017.05.007. Epub 2017 May 10.

PMID:
28655599
6.

Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106.

Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ.

J Community Support Oncol. 2015 Mar;13(3):87-94. doi: 10.12788/jcso.0114.

7.

Hematopoietic stem cell transplant candidate and designated proxy distress levels prior to hematopoietic stem cell transplantation.

Duckworth KE, Forti AM, Russell GB, Naik S, Hurd DD, McQuellon RP.

Am J Hosp Palliat Care. 2014 Dec;31(8):853-6. doi: 10.1177/1049909113508217. Epub 2013 Oct 17.

8.

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology.

Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23.

9.

Lenalidomide after stem-cell transplantation for multiple myeloma.

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C.

N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.

10.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL.

Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21.

11.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA.

Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15.

PMID:
21879809
12.

A validation study of new cryopreservation bags for implementation in a blood and marrow transplant laboratory.

Pomper GJ, Wilson E, Isom S, Hurd DD.

Transfusion. 2011 Jun;51(6):1291-5. doi: 10.1111/j.1537-2995.2010.02994.x. Epub 2010 Dec 22.

13.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2011 Apr;52(4):587-96. doi: 10.3109/10428194.2010.543714. Epub 2011 Jan 28.

14.

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW.

Ann Oncol. 2011 Apr;22(4):939-46. doi: 10.1093/annonc/mdq457. Epub 2010 Oct 8.

PMID:
20935058
15.

Specific alpha- and beta-tubulin isotypes optimize the functions of sensory Cilia in Caenorhabditis elegans.

Hurd DD, Miller RM, Núñez L, Portman DS.

Genetics. 2010 Jul;185(3):883-96. doi: 10.1534/genetics.110.116996. Epub 2010 Apr 26.

16.

Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature.

Keung YK, Beaty MW, Pettenati M, Levitan D, Hurd DD.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):129-33. doi: 10.3816/CLML.2010.n.018. Review.

PMID:
20371446
17.

Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction.

Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J.

J Soc Integr Oncol. 2010;8(4):140-147.

18.

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.

J Clin Oncol. 2009 Dec 20;27(36):6101-8. doi: 10.1200/JCO.2009.22.2554. Epub 2009 Nov 16.

19.

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP; Cancer and Leukemia Group B; Southwest Oncology Group; National Cancer Institute of Canada Clinical Trials Group.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1305-13. doi: 10.1016/j.ijrobp.2009.04.013. Epub 2009 Sep 9.

20.

A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions.

Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ.

Transfusion. 2008 Nov;48(11):2285-91. doi: 10.1111/j.1537-2995.2008.01858.x. Epub 2008 Jul 30.

PMID:
18673350
21.

A microcosm of the biomedical research experience for upper-level undergraduates.

Hurd DD.

CBE Life Sci Educ. 2008 Summer;7(2):210-9. doi: 10.1187/cbe.07-09-0089.

22.

High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.

Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP.

J Clin Oncol. 2008 May 10;26(14):2240-3. doi: 10.1200/JCO.2007.14.7827. No abstract available.

PMID:
18467711
23.

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.

Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA.

Leuk Lymphoma. 2008 Jul;49(7):1274-8. doi: 10.1080/10428190802043887.

24.

Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.

Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A.

Pharmacotherapy. 2007 Oct;27(10):1353-60.

PMID:
17896890
25.

Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).

Molnár I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Chen TC, Holick MF, Cambra S, McQuellon RP, Schwartz GG.

Leukemia. 2007 May;21(5):1089-92. Epub 2007 Mar 8. No abstract available.

PMID:
17344922
26.

Copper deficiency causes reversible myelodysplasia.

Huff JD, Keung YK, Thakuri M, Beaty MW, Hurd DD, Owen J, Molnár I.

Am J Hematol. 2007 Jul;82(7):625-30.

27.

Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?

Klepin HD, Hurd DD.

Bone Marrow Transplant. 2006 Nov;38(9):585-92. Epub 2006 Sep 4. Review.

PMID:
16953209
28.

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.

J Clin Oncol. 2006 Feb 20;24(6):929-36. Epub 2006 Jan 23. Erratum in: J Clin Oncol. 2006 Jun 10;24(17):2687. Moore, Dennis F Jr [added].

PMID:
16432076
29.

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.

Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E.

Cancer. 2005 Oct 15;104(8):1580-9.

30.

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, Richardson PG, Schuster MW, Marks LB, Cirrincione C, Norton L, Henderson IC, Schilsky RL, Hurd DD.

J Clin Oncol. 2005 Apr 1;23(10):2191-200. Epub 2005 Mar 14.

PMID:
15767638
31.

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, Velez-Garcia E, Moore JO, Shea TC, Hoke E, Caligiuri MA, Vardiman JW, Bloomfield CD, Larson RA; Cancer and Leukemia Group B.

J Clin Oncol. 2004 Nov 1;22(21):4290-301.

PMID:
15514371
32.

A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.

Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, Shea TC, Brunvand MM, Vaughan W, Petersen F, Schubert M, Lazarus HM, Maziarz RT, Silverman M, Beveridge RA, Redman R, Pulliam JG, Devitt-Risse P, Fuchs HJ, Hurd DD.

Leuk Res. 2004 Jun;28(6):559-65.

PMID:
15120931
33.

Constitutional pericentric inversion of chromosome 9 and bone marrow transplantation.

Keung YK, Knovich MA, Hurd DD, Pettenati M.

Br J Haematol. 2003 Nov;123(4):748-9. No abstract available.

PMID:
14616986
34.

A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).

Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ; PROMPT-CT Trial Investigators.

Leuk Lymphoma. 2003 Jul;44(7):1165-72.

PMID:
12916869
35.

Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.

Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA.

Cancer. 2003 Mar 15;97(6):1471-80.

36.

Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant.

Zamkoff KW, Bergman S, Beaty MW, Buss DH, Pettenati MJ, Hurd DD.

Bone Marrow Transplant. 2003 Feb;31(3):219-22.

PMID:
12621485
37.

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ.

J Clin Oncol. 2003 Jan 1;21(1):5-15.

PMID:
12506163
38.

PAR-1 is required for morphogenesis of the Caenorhabditis elegans vulva.

Hurd DD, Kemphues KJ.

Dev Biol. 2003 Jan 1;253(1):54-65.

39.
41.

Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.

Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR.

Ann Intern Med. 2002 Jul 16;137(2):77-87.

PMID:
12118962
42.

Allogenic marrow grafts from unrelated donors with congenital pericentric inversion of chromosome 9.

Keung YK, Pettenati M, Hurd DD, Powell BL, Buss DH.

Br J Haematol. 2002 Jan;116(1):237-8. No abstract available.

PMID:
11848092
43.

Control of Drosophila perineurial glial growth by interacting neurotransmitter-mediated signaling pathways.

Yager J, Richards S, Hekmat-Scafe DS, Hurd DD, Sundaresan V, Caprette DR, Saxton WM, Carlson JR, Stern M.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10445-50. Epub 2001 Aug 21.

44.

The C. elegans zyg-1 gene encodes a regulator of centrosome duplication with distinct maternal and paternal roles in the embryo.

O'Connell KF, Caron C, Kopish KR, Hurd DD, Kemphues KJ, Li Y, White JG.

Cell. 2001 May 18;105(4):547-58.

45.

Kinesins in the nervous system.

Martin MA, Hurd DD, Saxton WM.

Cell Mol Life Sci. 1999 Oct 15;56(3-4):200-16. Review.

PMID:
11212348
46.

Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.

Abruzzese E, Radford JE, Miller JS, Vredenburgh JJ, Rao PN, Pettenati MJ, Cruz JM, Perry JJ, Amadori S, Hurd DD.

Blood. 1999 Sep 1;94(5):1814-9.

PMID:
10477708
47.

Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

Perry JJ, Fleming RA, Rocco MV, Petros WP, Bleyer AJ, Radford JE Jr, Powell BL, Hurd DD.

Bone Marrow Transplant. 1999 Apr;23(8):839-42.

48.

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH.

N Engl J Med. 1998 Dec 3;339(23):1649-56.

49.

Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year.

McQuellon RP, Russell GB, Rambo TD, Craven BL, Radford J, Perry JJ, Cruz J, Hurd DD.

Bone Marrow Transplant. 1998 Mar;21(5):477-86.

50.

Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.

Owens D, Fleming RA, Restino MS, Cruz JM, Hurd DD.

Am J Health Syst Pharm. 1997 Mar 15;54(6):683-6. No abstract available.

PMID:
9075499

Supplemental Content

Support Center